Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.73 |
| ▸ | MME | P08473 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | MMP8 | P22894 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | CA12 | O43570 | 1/20 | 0.53 |
| ▸ | CA1 | P00915 | 1/20 | 0.53 |
| ▸ | CA2 | P00918 | 1/20 | 0.53 |
| ▸ | CA3 | P07451 | 1/20 | 0.53 |
| ▸ | CA4 | P22748 | 1/20 | 0.53 |
| ▸ | CA6 | P23280 | 1/20 | 0.53 |
| ▸ | CA5A | P35218 | 1/20 | 0.53 |
| ▸ | CA7 | P43166 | 1/20 | 0.53 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.53 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.53 |
| ▸ | CA9 | Q16790 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8930750 | 0.87 | KMT2A (0.76) | KMT2AMMEALDH1A1MEN1MAPT | |
| SCHEMBL7993179 | 0.86 | KMT2A (0.69) | KMT2AMMEALDH1A1MEN1MAPT | |
| SCHEMBL5016485 | 0.86 | KMT2A (0.62) | KMT2AALDH1A1MEN1 | |
| SCHEMBL8760 | 0.85 | KMT2A (0.67) | KMT2AMMEALDH1A1MEN1MAPT | |
| SCHEMBL5023255 | 0.84 | TSHR (0.60) | KMT2AALDH1A1MEN1 | |
| SCHEMBL5016313 | 0.84 | MAPK1 (0.60) | KMT2AALDH1A1MEN1L3MBTL1 | |
| SCHEMBL371105 | 0.84 | KMT2A (0.67) | KMT2AMMEALDH1A1MEN1MAPT | |
| SCHEMBL5023071 | 0.84 | KMT2A (0.54) | KMT2AALDH1A1MEN1CYP2D6 | |
| Hydrochloric Acid SCHEMBL23235729 | 0.83 | KMT2A (0.65) | KMT2AMMEALDH1A1MEN1MAPT | |
| SCHEMBL146434 | 0.83 | KMT2A (0.65) | KMT2AMMEALDH1A1MEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100480248-C | Malonamide derivatives as gamma-secretase inhibitors | HOFFMANN LA ROCHE (CH) | 2009-04-22 | — | — | CN | disclosed |
| EP-1592684-B1 | MALONAMIDE DERIVATIVES AS GAMMA-SECRETASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2008-07-30 | — | — | EP | disclosed |
| US-7375099-B2 | secretase inhibitors; therapy for Alzheimer's disease | HOFFMANN-LA ROCHE INC. (US) | 2008-05-20 | — | — | US | disclosed |
| CN-1745076-A | Malonamide derivatives as gamma-secretase inhibitors | HOFFMANN LA ROCHE (CH) | 2006-03-08 | — | — | CN | disclosed |
| EP-1592684-A1 | MALONAMIDE DERIVATIVES AS GAMMA-SECRETASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-11-09 | — | — | EP | disclosed |
| US-20040220222-A1 | Malonamide derivatives | F. HOFFMAN-LA ROCHE AG, A SWISS COMPANY (CH) | 2004-11-04 | — | — | US | disclosed |
| WO-2004069826-A1 | MALONAMIDE DERIVATIVES AS GAMMA-SECRETASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-08-19 | — | — | WO | disclosed |
| EP-0362002-A1 | HIV protease inhibitors | MERRELL DOW PHARMACEUTICALS INC. (US) | 1990-04-04 | — | — | EP | disclosed |
| CN-1040582-A | New peptidase inhibitors | MERRELL DOW PHARMA (US) | 1990-03-21 | — | — | CN | disclosed |
| EP-0356595-A1 | Novel peptidase inhibitors | MERRELL DOW PHARMACEUTICALS INC. (US) | 1990-03-07 | — | — | EP | disclosed |
| CN-88100378-A | New peptidase inhibitors | — | 1988-10-05 | — | — | CN | disclosed |
| EP-0275101-A2 | Novel peptidase inhibitors | MERRELL DOW PHARMACEUTICALS INC. (US) | 1988-07-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220222-A1 | Malonamide derivatives | BACE1, BACE2, APP | KMT2A 1285/4885MME 7/4885ALDH1A1 887/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.